Avience Biomedicals Limited
Avience Biomedicals Limited is an NSE SME IPO raising ₹30.24 crores entirely through a fresh issue, with shares offered at a price band of ₹196–₹208 and listing scheduled for June 25, 2026.
Overview
About the Company
Avience Biomedicals Limited, founded in June 2024 and headquartered in Delhi, is an ISO-certified manufacturer, supplier, and exporter of molecular diagnostic products and medical devices. The company's portfolio spans rapid test kits (covering diseases like COVID-19, HIV, HBsAg, malaria, dengue and syphilis), biochemistry analysers and reagents, hematology analysers, molecular diagnostic solutions, and medical devices such as oxygen concentrators and viral transport media. It primarily serves pathology labs, microbiology labs, hospitals, and research centres across India and internationally, operating on B2B and B2G business models. Its manufacturing facility is located in Noida, Uttar Pradesh, and it holds ISO 9001, ISO 13485, GMP, and ZED MSME Gold certifications. As of January 31, 2026, the company employed 75 permanent and 33 contractual staff.
Company Details
📋 Objects of Issue (Use of Proceeds)
- › Partially finance capital expenditure for setting up a new manufacturing unit at industrial plot no. 70, Sector 28, in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh – estimated at ₹15.96 crores.
- › Meet working capital requirements of the company – estimated at ₹8.25 crores.
- › General corporate purposes.
✅ Strengths
- ✓ The company offers a diverse portfolio of diagnostic products covering rapid test kits, biochemistry and hematology analysers, molecular diagnostic kits, and related reagents.
- ✓ Its distribution network spans healthcare institutions across India and is progressively growing its international reach.
- ✓ Holds multiple quality certifications including ISO 9001, ISO 13485, GMP, and ZED MSME Gold, reflecting adherence to stringent quality standards.
- ✓ The manufacturing facility in Noida is equipped with advanced processing capabilities enabling a broad range of production activities.
- ✓ The company has significant industry experience and focuses exclusively on B2B and B2G markets, serving pathology labs, microbiology labs, hospitals, and research centres.
⚠️ Risks
- ! Changes in government regulations and healthcare policies could adversely impact business operations and financial performance.
- ! The company's success relies heavily on the continued availability and performance of its key management and technical personnel.
- ! Dependence on external logistics and transportation providers introduces supply chain risks that are beyond direct company control.
- ! Revenue and profitability are exposed to fluctuations in market demand and broader industry dynamics.
- ! The company is involved in certain ongoing legal proceedings related to commercial disputes and cheque dishonour matters, which could result in financial or reputational consequences.